Bifeprunox mesylate maintenance dose compositions and methods for using the same

Abstract

The present disclosure provides novel pharmaceutical dosage forms such as a maintenance treatment dose and methods for making the same, and methods for using said compounds and maintenance treatment doses to treat and prevent diseases and/or disorders.

1 - 34 . (canceled) 
     
     
         35 . A method of treating at least one central nervous system (CNS) disorder in a human patient in need thereof, comprising co-administering to the patient a pharmaceutical composition comprising an effective amount of bifeprunox, a crystalline polymorph of 7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate and at least one pharmaceutically acceptable excipient, and at least one other pharmaceutically active agent, wherein the effective amount of bifeprunox comprises a maintenance treatment dose. 
     
     
         36 . The method according to  claim 35 , wherein the at least one other pharmaceutically active agent is chosen from CYP2C9 inhibitors, CYP3A4 inhibitors, CYP2A4 inhibitors, CYP3A4 inducers, and any pharmacologically acceptable combination thereof. 
     
     
         37 . The method according to  claim 35 , wherein the at least one other pharmaceutically active agent is chosen from fluconazole, ketoconazole, paroxetine, carbamazepine, warfarin, lithium, prothrombin, famotidine, and any pharmacologically acceptable combination thereof.